Cargando…
Perplexing issues for convalescent immune plasma therapy in COVID-19
Convalescent immune plasma (CIP) therapy in coronavirus disease 2019 (COVID-19) is presently a trendy choice of treatment. On March 24, 2020, the United States Food and Drug Administration approved of CIP treatment for seriously ill COVID-19 patients as an emergency investigational new drug. The pre...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Health Directorate of Istanbul
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848483/ https://www.ncbi.nlm.nih.gov/pubmed/35284793 http://dx.doi.org/10.14744/nci.2021.73604 |